Quanterix Marks Leadership in Accelerating Neurology Research with 100-Publication Milestone

• The Association of Changes in Plasma Neurofilament Light and Tau Levels with Anesthesia and Surgery Results from the CAPACITY and ARCADIAN Studies: Published in JAMA Neurology, this study shows that general anesthesia and surgery may be associated with neuronal damage in the short term.
• Association of Plasma Neurofilament Light Chain with Neocortical Amyloid-β Load and Cognitive Performance in Cognitively Normal Elderly Participants: Published in the Journal of Alzheimer’s Disease, the study found that plasma NfL is inversely associated with cognitive performance in elderly individuals and furthermore, that the onset of axonal injury, reflected by increased plasma NfL, within the preclinical phase of AD may contribute to the pathogenesis of AD.
• Plasma phospho-tau181 increases with Alzheimer’s disease clinical severity and is associated with tau- and amyloid-positron emission tomography: Published in Alzheimer’s & Dementia, this study showed that Plasma pTau181 may have utility as a biomarker of AD pathophysiology and as a noninvasive screener for elevated brain Aβ.
• Serum neurofilament light chain is a biomarker of acute and chronic neuronal damage in early multiple sclerosis: Published in the Multiple Sclerosis Journal, found NfL to be a promising biomarker for the neuro-axonal damage in early multiple sclerosis patients.
• Neurofilament light chain and tau concentrations are markedly increased in the serum of patients with sporadic Creutzfeldt-Jakob disease, and tau correlates with rate of disease progression: Published in the Journal of Neurology, Neurosurgery & Psychiatry, this study showed clear promise for tau and NfL as blood-based biomarkers in prion disease.

For more information on Quanterix’ complete list of publications and posters, please visit: https://www.quanterix.com/resources/publications-posters

About Quanterix

Quanterix is a company that’s digitizing biomarker analysis with the goal of advancing the science of precision health. The company’s digital health solution, Simoa, has the potential to change the way in which healthcare is provided today by giving researchers the ability to closely examine the continuum from health to disease. Quanterix’ technology is designed to enable much earlier disease detection, better prognoses and enhanced treatment methods to improve the quality of life and longevity of the population for generations to come. The technology is currently being used for research applications in several therapeutic areas, including oncology, neurology, cardiology, inflammation and infectious disease. The company was established in 2007 and is located in Lexington, Massachusetts. For additional Information, please visit https://www.quanterix.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “may,” “will,” “expect,” “plan,” “anticipate,” “estimate,” “intend” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. Forward-looking statements in this news release are based on Quanterix’s expectations and assumptions as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties. Factors that may cause Quanterix’s actual results to differ from those expressed or implied in the forward-looking statements in this press release are discussed in Quanterix’s filings with the U.S. Securities and Exchange Commission, including the “Risk Factors” sections contained therein. Except as required by law, Quanterix assumes no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available.

View source version on businesswire.com: https://www.businesswire.com/news/home/20180427005083/en/